Related Experiment Video

Updated: Jun 2, 2025

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.5K

Identification of PLAC1 as a prognostic biomarker and molecular target in clear cell renal cell carcinoma

Ying Kong1, Zongming Jia1, Yizhang Sun1

  • 1Department of Urology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.

Cellular Signalling
|January 15, 2025
PubMed

Insights

Researchers identified placental protein 1 (PLAC1) as a promising target for clear cell renal cell carcinoma (ccRCC). Inhibiting PLAC1 shows potential for treating ccRCC, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Clear cell renal cell carcinoma (ccRCC) presents significant clinical challenges due to limited effective treatments.
  • Identifying novel molecular targets is crucial for advancing ccRCC therapy.

Purpose of the Study:

  • To investigate the role of PLAC1 in ccRCC development and progression.
  • To identify potential therapeutic agents targeting PLAC1 for ccRCC treatment.

Main Methods:

  • Analysis of TCGA database for PLAC1 expression.
  • Western blotting and immunofluorescence to validate PLAC1 levels.
  • In vitro experiments involving PLAC1 knockdown.
  • High-throughput virtual screening (HTVS) to identify PLAC1 inhibitors.

Main Results:

  • PLAC1 was found to be significantly overexpressed in ccRCC tissues.
  • High PLAC1 expression correlated with poor patient prognosis.
  • Knockdown of PLAC1 suppressed ccRCC cell proliferation in vitro.
  • AmB and Cana were identified as inhibitors that reduce PLAC1 expression and ccRCC progression.

Conclusions:

  • PLAC1 serves as a potential prognostic biomarker for ccRCC.
  • AmB and Cana demonstrate therapeutic potential by inhibiting ccRCC progression via PLAC1 reduction.
Keywords:
Amaronol BBiomarkersCanagliflozinClear cell renal cell carcinomaHTVSMolecular targetPLAC1

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K